STI-6129

STI-6129 is an investigational antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently linked to a duostatin tubulin inhibitor payload via a proprietary site-specific C-LockT chemical linker. The drug specifically targets CD38 (Lymphocyte differentiation antigen CD38), a cell surface antigen highly expressed on multiple myeloma and other hematologic malignancy cells. Upon binding to CD38, the ADC is internalized by tumor cells, where the duostatin payload inhibits tubulin polymerization, leading to G2/M phase cell cycle arrest and apoptosis. STI-6129 has been designed to reduce premature systemic release of its cytotoxic payload and minimize toxicity compared with earlier ADCs. It is being developed primarily for relapsed or refractory multiple myeloma and amyloid light-chain amyloidosis, including in patients resistant to existing anti-CD38 monoclonal antibodies such as daratumumab[1][4][5][6][8].

Other names

anti-CD38 antibody-drug conjugate STI-6129anti-CD-38 antibody-drug conjugate STI-6129anti-CD 38 antibody-drug conjugate STI-6129anti-CD38-Duostatin 5.2 antibody-drug conjugateanti-CD-38-Duostatin 5.2 antibody-drug conjugateanti-CD 38-Duostatin 5.2 antibody-drug conjugate